Paragon Biosciences CEO Jeff Aronin spoke with Crain’s Chicago Business on his role in the company, his vision for Paragon, and his mission to bring treatments to patients suffering from rare, genetic, debilitating diseases that too few companies focus on.
Paragon Biosciences CEO Jeff Aronin was recognized this week by Insights Care magazine for his innovative leadership in the biosciences sector and for his work bringing life-altering drugs to patients in need.
Harmony Biosciences, LLC (Harmony), a portfolio company of Paragon Biosciences (Paragon), was joined by Pennsylvania Governor Tom Wolf to announce the opening of its completed, 15,651 square-foot headquarters located in Plymouth Meeting, PA.
Paragon Biosciences (Paragon) today announced Skyline Biosciences (Skyline) as the newest addition to its growing portfolio of drug-development companies. Paragon identifies unmet patient needs, invests in the development of novel medicines, and incubates biopharmaceutical companies, such as Skyline.
Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in patients under 16 years of age.
Castle Creek Pharmaceuticals, LLC., a US-based company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. Food & Drug Administration (FDA) has designated as a Fast Track development program the investigation of diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS).
Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the first patient has been enrolled at UNC-Chapel Hill Dermatology & Skin Cancer Center in a new Phase 1 study evaluating the pharmacokinetics (PK) and safety of diacerein 1% ointment (CCP-020) under maximum use conditions in patients with epidermolysis bullosa (EB).
Harmony Biosciences, LLC (Harmony), a Paragon Biosciences, LLC, portfolio company, today announced that it will present scientific data on its investigational product, pitolisant, which is being studied for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy, at the upcoming 32nd Annual Meeting of the Associated Professional Sleep Societies, known as "SLEEP", in Baltimore, MD from June 3-6.
Harmony Biosciences, LLC (Harmony), today announced that it has received Breakthrough Therapy and Fast Track designations for its investigational product, pitolisant, from the U.S. Food and Drug Administration (FDA).